MSD has signed a global license agreement for a KRAS G12D inhibitor from China's SciBrunch Therapeutics, paying $400 million ...
Other candidates in its pipeline include injectable GIP/GLP-1 agonist enicepatide, injectable amylin analogue petrelintide, ...
Patients with fibrodysplasia ossificans progressiva (FOP) in the US will soon have the option of treatment with another daily ...
The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...
MSD and Daiichi Sankyo's regulatory efforts for their antibody-drug conjugates (ADCs) for cancer have stuttered again, with a ...
A team from the Garvan Institute of Medical Research in Darlinghurst, New South Wales, have used an emerging form of genetic ...
The off switch needs authority. The people carrying on after it is used need a budget. Editorial disclosure: The medicines ...
The Swiss pharma group has just reported topline results from the phase 3 IMAgINATION study of Factor B inhibitor sefaxersen ...
Adding ITM will also give Telix a pipeline of follow-up radiopharma candidates, including clinical-stage diagnostics and ...
Fayuvi is Ultragenyx's second approved gene therapy after Genglycos (pariglasgene brecaparvovec) for glycogen storage disease ...
Eli Lilly has continued a busy period of deal-making with a wide-ranging partnership with China's InnoCare Pharma that includes upfront and near-term payments of $100 million. There's another $3.25 ...
Chinese tech giant ByteDance – best known as the parent of social media app TikTok – has completed a $290 million financing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results